Biofrontera(BFRI) ZACKS·2024-11-14 01:11Core Insights - Biofrontera Inc. reported a quarterly loss of $0.86 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.73, marking an earnings surprise of -17.81% [1] - The company's revenues for the quarter ended September 2024 were $9.01 million, missing the Zacks Consensus Estimate by 18.15%, and showing a slight increase from $8.9 million a year ago [2] - Biofrontera's shares have declined approximately 66% since the beginning of the year, contrasting with a 25.5% gain in the S&P 500 [3] Financial Performance - Over the last four quarters, Biofrontera has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $14.21 million, while for the current fiscal year, it is -$3.07 on revenues of $40.97 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Biofrontera belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of Biofrontera's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]